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Background 
Procalcitonin (PCT) is a relatively new biomarker 
that aids in the diagnosing and monitoring of 
sepsis. Its levels begin to rise as soon as 3 – 6 
hours after an infection is detected by the 
immune system. In academic and research 
centers, it has shown to be an early and highly 
specific marker in response to sepsis and 
severe systemic bacterial infections. 
Purpose 
Explore and describe the use of PCT in a 
community hospital setting to include: 
 A review of its diagnostic accuracy in 
predicting sepsis and if it is useful as an early 
marker. 
 A review of PCT’s utilization on direct cost 
and length of stay (LOS) for sepsis patients.  
Methods 
Two methods are being utilized:  
    Method 1: Exploratory descriptive case-
control study using a secondary analysis of 
retrospective data over an 8-month period after 
implementation of PCT. 
    Method 2: Retrospective quasi-experimental 
study using a historical control group of an  
8-month period before implementation of PCT. 
Table 1: Septic patient characteristics and outcomes  
from January 2014-July 2015 (n=233) 
Figure 1: Method 1 – Data collected from January 2014 – July 2015  
Preliminary Findings 
The preliminary results in Table 1 show 233 
cases of which:  
    The majority of patients were 70 years or                      
older (62.7%) and White Hispanic (76.8%). 
    Nearly half (49.4%) required discharge to 
a specialty nursing facility. 
    Both LOS (1-102 days) and direct 
hospital cost ($1,306 to $197, 862) vary 
widely between patients. 
    There is a significant  correlation 
between PCT and lactic acid levels  
(Figure 1: r = 0.377, p < 0.001).  
Discussion 
A diagnosis of sepsis has profound 
implications for our older patient population 
and the hospital including extended LOS, 
extended recovery after discharge, and high 
cost.  Lactic acid have been considered the 
gold-standard marker for sepsis. We have 
demonstrated good correlation, in a 
community hospital setting, between PCT 
and lactic acid levels, suggesting that the 
earlier rise of PCT may be advantageous for 
diagnosing and treating sepsis.  These 
preliminary results will drive the second 
portion of the study which will review direct 
cost and LOS pre- and post-implementation 
of PCT use. 
Implications for Practice 
If PCT implementation results in improved 
outcomes, LOS and / or cost, consideration 
should be given to expanding its use 
throughout the Baptist Health South Florida 
system. 
